INSMED Inc. Files 8-K Report

Ticker: INSM · Form: 8-K · Filed: 2025-02-24T00:00:00.000Z

Sentiment: neutral

Topics: filing, financials

Related Tickers: INSM

TL;DR

INSMED filed an 8-K, mostly financial docs. Stay tuned for details.

AI Summary

On February 24, 2025, INSMED Incorporated filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates INSMED Inc. is providing updated information to the SEC, which could include financial details or disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not appear to contain negative news or significant changes.

Key Players & Entities

FAQ

What specific financial statements were included in the 8-K filing?

The provided excerpt indicates that 'Financial Statements and Exhibits' were part of the filing, but does not specify which particular statements were included.

What was the date of the earliest event reported in this 8-K?

The date of the earliest event reported is February 24, 2025.

What is INSMED Incorporated's state of incorporation?

INSMED Incorporated is incorporated in Virginia.

What is the primary business address for INSMED Inc.?

The primary business address is 700 US Highway 202/206, Bridgewater, New Jersey 08807.

What items are specifically mentioned as being covered by this 8-K filing?

The filing covers Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

From the Filing

0001140361-25-005570.txt : 20250224 0001140361-25-005570.hdr.sgml : 20250224 20250224080016 ACCESSION NUMBER: 0001140361-25-005570 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250224 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250224 DATE AS OF CHANGE: 20250224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 25654267 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 8-K 1 ef20044166_8k.htm 8-K false 0001104506 0001104506 2025-02-24 2025-02-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 700 US Highway 202/206 Bridgewater , New Jersey   08807 (Zip Code) (Address of principal executive offices)     Registrant’s telephone number, including area code: ( 908 ) 977-9900 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share INSM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ITEM 8.01 — Other Events. On February 24, 2025, Insmed Incorporated (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) does not currently plan to hold an advisory committee meeting to discuss the Company’s New Drug Application (“NDA”) for brensocatib for patients with non-cystic fibrosis bronchiectasis. The FDA previously granted the Company’s request for priority review and set a target action date of August 12, 2025 under the Prescription Drug User Fee Act. ITEM 7.01 — Regulation FD Disclosure. On February 24, 2025, the Company issued a press release announcing that the FDA does not currently plan to hold an advisory committee meeting to discuss the Company’s NDA for brensocatib for pati

View on Read The Filing